A fluid sample container comprising a protease, when a sample fluid is placed in the fluid sample container the protease breaking a target analyte in the sample fluid into at least two peptides, the at least two peptides being smaller than the original target analyte.

A method of proteolyzing a protein, including immobilizing a protein in at least one pore of a porous body, and contacting the protein immobilized in the pore and a protease immobilized on a solid surface such that the protease selectively accesses a site of the protein and proteolyzes the protein at the site.

A fluid sample container comprising a protease, when a sample fluid is placed in the fluid sample container the protease breaking a target analyte in the sample fluid into at least two peptides, the at least two peptides being smaller than the original target analyte.

A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed.

Methods and kits for preparing liquid samples are presently claimed and described. The method may include treating liquid sample with a hydrolysis enzyme, hydrolyzing the liquid sample to prepare a hydrolysate, and purifying the hydrolysate with magnetic based purification. In certain aspects, the hydrolysis enzyme is bound to a magnetic bead or a magnetic particle. Kits for preparing a liquid sample can include a hydrolysis enzyme, magnetic beads or magnetic particles, one or more internal standards, a liquid chromatography column and one or more solvents to be used as mobile phases, one or more calibrant solutions and instructions for use.

The subject of the invention is a new compound of the following chemical formula:

ABZ.sup.1-Dap(O2(Cbz)).sup.2-Dap(O1).sup.3-Dap(O2).sup.4-Arg.sup.5-ANB.sup.6-NH.sub.2 where: ABZ stands for 2-aminobenzoic acid; DAP stands for diaminopropanoic acid (Dap) derivatives, modified by the functionalised residues of mono-ethylene or diethylene glycol (PEG); ANB stands for 5-amino-2-nitrobenzoic acid

The subject of the invention is a method for producing the new compound and a pharmaceutical solution for cancer detection, which contains the above-mentioned compound.

The subject of the invention is a method for cancer detection through the in vitro analysis of a human urine sample to which a new compound is added and blended with a buffer of pH 7-9.

The subject of the invention is also a kit for detecting cancer, in particular bladder cancer, and the use of hydrolysis of the new compound in the position no. 5 by proteasome 20s for cancer detection, in particular bladder cancer.

Compounds comprising an isobaric region, an enrichment handle, and a thiol-reactive group are generally described. Methods of using the same (e.g., performing multiplexed quantitative analysis of the reactivity of one or more cysteine residues across multiple samples simultaneously) are also described.

The disclosure provides methods of forming one or more single-cell proteomic samples, such as by: dispensing n droplets of lysis buffer onto a substantially planar solid surface, wherein n>2: dispensing a single cell into each of the n droplets of lysis buffer to produce n droplets with a lysed single cell: dispensing digestion buffer into each of the n droplets to digest proteins from each lysed single cell to produce n droplets comprising peptides: dispensing a chemical tag into at least a subset of the n droplets comprising the peptides to produce labeled peptides, thereby enabling the labeled peptides in a given droplet to be distinguishable from labeled peptides in at least one other droplet: and applying a fluid to merge at least a subset of the droplets into a combined droplet on the substantially planar surface, thereby combining the labeled peptides to form a single-cell proteomic sample.

The present disclosure provides a range of compositions and methods for enriching subsets of complex biological samples. Aspects of the present disclosure provide peptide-functionalized particles comprising affinities for subsets of biomolecules from complex biological samples. The present disclosure further provides methods for utilizing functionalized particles to fractionate and analyze complex biological samples.

Disclosed herein are compositions for use in methods of evaluating gap junction formation, methods of interrogating the docking interactions between connexins, and methods of high-throughput quantification of gap junction hemichannel docking.